Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service kidney stone management cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 108 | 6,197 | 45% |
| 2020 | 97 | 5,203 | 51% |
| 2021 | 96 |
Ureteroscopy with laser lithotripsy, ESWL, PCNL. Professional codes (what the surgeon bills): CPT 52356, 52353, 52352, 50590, 50080, 50081.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 25% of the cases CMS names in Michigan; 61 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| BPH procedures | 40 | 3,700−3.6%/yr | −3.6%/yr | 4.30.9× | 29% | 3,320 in 2030−1.8%/yr |
| Hysterectomy, hysteroscopy & ablation |
Kidney stone management in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Ohio
| 2024 |
| 4,688 |
| 66% |
| 2025 est. | ≈ 4,490 | – |
| 2026 est. | ≈ 4,530 | – |
| 5,245 |
| 55% |
| 2022 | 95 | 4,865 | 59% |
| 2023 | 86 | 4,659 | 63% |
| 2024 | 94 | 4,688 | 66% |
| 2025 from claims | – | 4,494 4,124–4,754 | 67% |
| 2026 forecast | – | 4,533 3,988–5,231 | 67% |
| 2027 forecast | – | 4,523 3,867–5,391 | 68% |
| 2028 forecast | – | 4,511 3,764–5,524 | 69% |
| 2029 forecast | – | 4,497 3,673–5,639 | 70% |
| 2030 forecast | – | 4,479 3,588–5,740 | 70% |
In 2025, 9% inpatient hospital, 85% hospital outpatient, 6% surgery center. The share outside the hospital has moved −2 pts since 2019.
| −2.8%/yr |
| 4.5 |
| 13% |
| 6,630 in 2030+1.2%/yr |
| Indiana | 105 | 5,228−0.5%/yr | −0.5%/yr | 7.5 | 11% | 6,130 in 2030+2.7%/yr |
| Missouri | 83 | 3,766−2.6%/yr | −2.6%/yr | 6.1 | 19% | 4,330 in 2030+2.4%/yr |
| Wisconsin | 63 | 2,490−3.4%/yr | −3.4%/yr | 4.5 | 6% | 2,900 in 2030+2.6%/yr |
| Kansas | 44 | 2,107−0.8%/yr | −0.8%/yr | 5.2 | 20% | 2,660 in 2030+4%/yr |
| Minnesota | 47 | 1,837−5.2%/yr | −5.2%/yr | 4.1 | 5% | 2,500 in 2030+5.3%/yr |
| Iowa | 47 | 1,750−0.8%/yr | −0.8%/yr | 4.0 | 26% | 1,840 in 2030+0.9%/yr |
| Nebraska | 35 | 1,512−0.1%/yr | −0.1%/yr | 5.8 | 12% | 1,880 in 2030+3.7%/yr |
| South Dakota | 18 | 618+1.8%/yr | +1.8%/yr | 4.8 | 0% | 810 in 2030+4.6%/yr |
| North Dakota | 10 | 352−6.2%/yr | −6.2%/yr | 3.6 | 0% | 360 in 2030+0.5%/yr |
| 15 |
| 2,577−6%/yr |
| −6%/yr |
| 3.41.2× |
| 11% |
| 2,550 in 2030−0.1%/yr |
| Incontinence, prolapse & sacral neuromodulation | 25 | 1,789−6.7%/yr | −6.7%/yr | 2.10.9× | 4% | 1,480 in 2030−3.1%/yr |
| Prostatectomy & nephrectomy | 10 | 897−4.5%/yr | −4.5%/yr | 1.20.8× | 0% | 1,150 in 2030+4.2%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 79% of company spending on these surgeons in 2025, +30 pts on 2024.
In 2025, 4 companies reported engagement with Michigan’s surgeons worth $88K in consulting, speaking, meals and travel tied to these products, about $931 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.